logo
  

Adamis Pharma Reports FDA Approval Of ZIMHI In Treatment Of Opioid Overdose - Quick Facts

Adamis Pharmaceuticals Corporation (ADMP) announced the FDA has approved ZIMHI 5 mg/0.5 mL, a high-dose naloxone injection for use in the treatment of opioid overdose. The company is preparing for the full commercial launch of ZIMHI in the first quarter of 2022.

Dennis Carlo, CEO of Adamis, said, "We are very excited by this approval and are working with our commercial partner, US WorldMeds, to make this much-needed, lifesaving product readily available to the market."

Shares of Adamis Pharmaceuticals Corporation were up 23% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, said it is launching more options on WhatsApp to control their messages and how long they stick around, with default disappearing messages and multiple durations. The latest features are expected to bring more control and privacy on the popular messaging app. Delivery services company DoorDash has introduced ultra-fast grocery deliveries with DashMart in Chelsea, New York City. The company said it aims to deliver in 10-15 minutes and plans to expand its new service in select DoorDash grocery and convenience partners over the next year. With over 2,000 items, DashMart offers a wide assortment of fresh and frozen grocery staples, snacks, household goods, and local products. Ontario, Canada-based Erie Meat Products Ltd. is recalling approximately 1,224 pounds of fully cooked chicken bologna products, according to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS. The chicken bologna products were imported and distributed into the United States without the benefit of FSIS import reinspection.
RELATED NEWS
Follow RTT